Wire · operational-macro
Edwards Lifesciences Wins FDA Approval for PASCAL Precision Tricuspid Valve Repair System
◆ Sectors
◆ Geography
◆ Source
◆ Verified
Fusion42 · 3 November 2026 · Fusion42 review
Edwards Lifesciences has received FDA approval for its PASCAL Precision system for transcatheter repair of the tricuspid valve, targeting patients with symptomatic severe tricuspid regurgitation at intermediate or higher surgical risk. This approval expands Edwards' tricuspid treatment options alongside its EVOQUE replacement system, positioning it competitively against Abbott's TriClip.
This Wire brief sits within Fusion42's coverage of Medtech, and 6 sources have reported it between 21 Oct 2026 and 3 Nov 2026.
◆ ◆ The Wire takeaway
You must understand Edwards' newly approved PASCAL Precision repair device as it opens patient segments at surgical risk, forcing you to position it clearly against Abbott's TriClip in sales discussions. The approval invites you to refine patient targeting and clinical conversations now that repair and replacement live side by side within Edwards' portfolio.
◆ Coverage
6 sources · first reported 21 Oct 2026 · latest 3 Nov 2026
◆ Related on Wire
◆ Topics